Afatinib is approved for the treatment of NSCLC either with activating EGFR mutation or in squamous cell carcinoma under or after progression on platinum-based chemotherapy and is efficacious in tumor models at dosages from 20 mg/kg or higher once a day27. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.